<DOC>
	<DOCNO>NCT03033927</DOCNO>
	<brief_summary>The purpose phase II study develop test predict response pancreatic cancer different chemotherapy regimen .</brief_summary>
	<brief_title>Predicting Effective Therapy Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Histological cytological diagnosis pancreatic adenocarcinoma , confirm MSKCC , AJCC stage IV disease time enrollment . Patient plan receive treatment FOLFIRINOX gem/nabP chemotherapy , without investigational agent . Prior surgery , chemotherapy and/or radiation therapy AJCC Stage IIII pancreatic adenocarcinoma permit . ECOG performance status 02 . A minimum age 18 year old . Prior chemotherapy AJCC stage IV pancreatic adenocarcinoma Known HIV positive antiretroviral therapy Prior organ allograft Any medical psychiatric condition may interfere ability comply protocol procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Stage IV Pancreatic Cancer</keyword>
	<keyword>FOLFIRINOX</keyword>
	<keyword>gem/nab-P chemotherapy</keyword>
	<keyword>17-042</keyword>
</DOC>